Chinese biopharmaceutical "Adfowe ester capsules" through consistency evaluation.

Guide: It is the first product of the same species to be evaluated by generic drug quality and efficacy consistency. on August 4,
, China Biopharma announced that the Group's treatment of hepatitis B drug "Adfoweeste Capsules" (trademark name: zheng) has been issued by the State Drug Administration of the People's Republic of China drug supplement approval notice, becoming the first product of the same species through generic quality and efficacy evaluation, for the treatment of hepatitis B virus activity replication evidence, accompanied by serum amino acid transfer enzymes continuously elevated or liver disease activity of chronic hepatitis B patients.
Adfoweest is a precursor to Adfowe, which in vivo hydrolysis plays an antiviral role for Adfowe.
Adfoviris is a drug that is now less cross-resistant in domestic hepatitis B antiviral drugs and is therefore also used in combination with other drugs.
With the gradual increase in the rate of ramirez resistance, Adfovir has gradually replaced ramifudine as a first-line drug for the treatment of hepatitis B.
.